Theres a second problem: muscle loss
Phase 2: Maintenance (Every Other Day) Most Important Goal: Sustain results with the lowest effective dose
Among the 3,532 participants in the FLOW trial, 19.2% (678 individuals) had heart failure at baseline, with 47.9% classified as having HFpEF, 18.1% as having heart failure with reduced ejection fraction (HFrEF), and 33.9% with unknown status
Safety, Risks, and Responsible Use of ColonBroom GLP-1 Booster When reading ColonBroom GLP-1 Booster reviews and complaints in 2025, safety is a top concern
consider withholding SGLT-2i if volume depletion risk is high
TRIUMPH-2 will support a potential combined obesity-and-diabetes indication